Efficacy of tobramycin dexamethasone combined with loteprednol in the treatment of anterior uveitis and its impact on serum IgG, IgA, and IgE

Objective of the present study is to investigate the efficacy of tobramycin dexamethasone combined with loteprednol for the treatment of anterior uveitis and its impact on serum IgG, IgA and IgE. 72 patients with anterior uveitis were randomly divided into study group and control group. The study group was treated with tobramycin dexamethasone and loteprednol, while the control group was only treated with tobramycin dexamethasone. All patients were followed up for six weeks. The clinical efficacy, healing time, side effects, serum IgG, IgA and IgE changes were compared between the two groups. The clinical efficacy of the study group was significantly better than the control group; the healing time of the study group was shorter than the control group; the incidence of adverse reactions of the study group was 2.78% lower than 16.67% of the control group. There were significant differences between the two groups (P<0.05). After the treatment, the serum IgG and IgE levels in the study group were significantly lower than the control group. However, IgA level was higher in the study group (P<0.05). The efficacy of tobramycin dexamethasone combined with loteprednol for treating anterior uveitis is certainly better than tobramycin dexamethasone alone. The serum IgG and IgE levels were significantly reduced and the serum IgA levels were significantly increased, so it should be widely applied in clinical practice.